CVRx Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

CVRx hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.7%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$2.50
Prognose der Dividendenrendite	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Jul 31

Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge

Jun 18

Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

Feb 18

CVRx: The Path To 7x Investment Returns

Jan 07

CVRx: High Risk And High Potential Reward

Jul 04

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von CVRX in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von CVRX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

CVRx Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von CVRX im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (CVRX)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Medical Equipment)	1.7%
Analystenprognose (CVRX) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von CVRX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von CVRX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von CVRX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da CVRX keine Ausschüttungen gemeldet hat.

CVRx Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

CVRx, Inc. Announces Board Changes

President recently bought US$251k worth of stock

CVRx, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Second quarter 2024 earnings: EPS misses analyst expectations

CVRx, Inc. to Report Q2, 2024 Results on Jul 29, 2024

CVRx, Inc.(NasdaqGS:CVRX) dropped from Russell Small Cap Comp Value Index

CVRx, Inc. Announces Appointment of Robert Allen John as Chief Revenue Officer, Effective June 27, 2024

Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge

New major risk - Share price stability

CVRx, Inc. Announces Executive Appointments

Consensus EPS estimates fall by 28%

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%

CVRx, Inc. Provides Earnings Guidance for Second Quarter and Full Year of 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CVRx, Inc., Annual General Meeting, Jun 04, 2024

CVRx, Inc. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Shareholder dilution

Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%

Chief Marketing & Strategy Officer notifies of intention to sell stock

CVRx, Inc. Announces Chief Executive Officer Changes, Effective February 12, 2024

CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12, 2024

CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12

Full year 2023 earnings: EPS exceeds analyst expectations

CVRx, Inc. to Report Q4, 2023 Results on Jan 25, 2024

CVRx, Inc. Announces Nadim Yared Retires as Chief Executive Officer

CVRx, Inc. Announces Nadim Yare Retires as President

CVRx, Inc. Receives FDA Approval for Expanded Labing of Barostim

Price target increased by 16% to US$23.60

Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%

New minor risk - Share price stability

CVRx, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Price target decreased by 9.3% to US$19.40

CVRx, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. Revises Financial Guidance for the Full Year 2023

CVRx, Inc. to Report Q2, 2023 Results on Jul 25, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. to Report Q4, 2022 Results on Jan 26, 2023

CVRx, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022 and Provides Revenue Guidance for the First Quarter and Full Year of 2023

CVRx, Inc. Appoints Kevin Hykes to Board of Directors

Price target increased to US$17.25

Chief Marketing & Strategy Officer notifies of intention to sell stock

Price target increased to US$14.75

CVRx, Inc. Launches New Barostim NEO2(TM) Implantable Pulse Generator

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. announced that it expects to receive $65 million in funding from Innovatus Capital Partners, LLC

CVRx, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth

CVRx Pursues Revenue Growth But Operating Losses Worsen

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CVRx, Inc. Revises Earnings Guidance for the Full Year of 2022

CVRx, Inc. to Report Q2, 2022 Results on Jul 28, 2022

CVRx, Inc. Launches A New Barostim Programmer

CVRx, Inc.(NasdaqGS:CVRX) dropped from Russell 2500 Value Index

CVRx: Barostim Story Looks Well Priced In, Overvalued At Just 5x Sales

CVRx, Inc. Receives U.S. Food and Drug Administration Approval for Magnetic Resonance Conditional Labeling for Its Barostim System

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

CVRx, Inc., Annual General Meeting, Jun 07, 2022

CVRx, Inc. to Report Q1, 2022 Results on Apr 25, 2022

We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth

Consensus forecasts updated

Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

Full year 2021 earnings: EPS exceeds analyst expectations

CVRx, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

CVRx, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Cvrx, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2021 and First Quarter and Full Year of 2022

CVRx: The Path To 7x Investment Returns

Third quarter 2021 earnings released: US$0.30 loss per share

CVRx, Inc. Provides Earnings Guidance for the Third Quarter of 2021; Provides Earnings Guidance for the Year 2021

CVRx: High Risk And High Potential Reward

CVRx, Inc. has completed an IPO in the amount of $126 million.